Genomic expression, chemotherapy response, and molecular targets in soft tissue sarcomas of the extremities: promising strategies for treatment selection.
Neoadjuvant or adjuvant therapy in soft tissue sarcomas is still controversial, especially in regards to the use of chemotherapy. The identification of predictive factors is crucial to avoid the use of chemotherapy in patients with tumors that carry genetic characteristics associated with resistance. Focusing on gene expression data, we performed a review of the actual state of knowledge in molecular predictive factors for chemotherapy response and new targets of therapy in extremity sarcomas.
Aguiar
Samuel
S
Department of Pelvic Surgery, A.C. Camargo Cancer Hospital, Sao Paulo, SP, Brazil. samuel.aguiar.jr@uol.com.br
da Cunha
Isabela Werneck
IW
Lopes
Ademar
A
D017024:Chemotherapy, Adjuvant; D005121:Extremities; D020869:Gene Expression Profiling; D006801:Humans; D018579:Patient Selection; D012509:Sarcoma / Q000188:drug therapy* / Q000235:genetics*